Reviva Pharmaceuticals shares are trading higher after the company announced its pivotal Phase 3 RECOVER trial evaluating the efficacy, safety and tolerability successfully met its primary endpoint.
Reviva Pharmaceuticals Holdings Inc. Ordinary Shares -4.00%
Reviva Pharmaceuticals Holdings Inc. Ordinary Shares RVPH | 1.44 | -4.00% |
Reviva Pharmaceuticals shares are trading higher after the company announced its pivotal Phase 3 RECOVER trial evaluating the efficacy, safety and tolerability successfully met its primary endpoint.